Sino Biological has created a VLP protein platform based on the HEK293 expression system for producing full-length multi-pass transmembrane proteins (e.g. GPRC5D).

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has pushed the world towards developing rushed but effective vaccines against ...

Virus-like particles (VLPs) are protein-based structures that mimic viruses and bind to antibodies. Because VLPs aren't infectious, they show promise as vaccine platforms for many viral diseases ...

Eluate containing VLP’s was diluted with 20 mM Tris-HCl ... 10 µg/mL or 100 µg/mL resulted in loss of the drug due to protein adherence to the vial. Formulation studies utilizing Schott ...

Icosavax’s VLP technology was licensed from the University of Washington’s Institute for Protein Design. Simpson said his company’s approach could address pathogens that have eluded vaccine ...

Both candidates, and others being developed by the company, use a virus-like particle (VLP) technology developed at UW’s Institute for Protein Design (IPD). “[VLPs] work well with related ...

This observation that the S protein mutations have little to ... luciferase and mRNA delivery activity in SARS-CoV-2 virus-like particles, the researchers then reverse-engineered SARS-CoV-2 ...

The high yield and stability of the protein components and assembled nanoparticles suggest that manufacture of the nanoparticle vaccines will be highly scalable. About IVX-411, COVID-19 VLP ...

“It’s really a protein folding and manufacturing problem. The complex antigens displayed on the VLP need to be properly folded to provide a protective immune response, without interfering with ...

Particulate vaccines are usually made of a scaffold of protein-based virus-like particles carrying many copies of a viral antigen. Because they mimic a natural virus, these vaccines can create a ...